ABVC BioPharma (NASDAQ:ABVC) Stock Price Up 0.9% – Still a Buy?

Shares of ABVC BioPharma, Inc. (NASDAQ:ABVC) rose 0.9% during trading on Friday . The stock traded as high as $1.10 and last traded at $1.09. Approximately 68,611 shares changed hands during mid-day trading, a decline of 7% from the average daily volume of 73,972 shares. The stock had previously closed at $1.08.

Analysts Set New Price Targets

Separately, Weiss Ratings raised ABVC BioPharma from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company has an average rating of “Sell”.

ABVC BioPharma Stock Performance

The company has a 50-day simple moving average of $1.20 and a 200-day simple moving average of $1.86. The stock has a market cap of $27.73 million, a P/E ratio of -2.73 and a beta of 0.42.

ABVC BioPharma (NASDAQ:ABVC) last issued its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.11) earnings per share (EPS) for the quarter.

Hedge Funds Weigh In On ABVC BioPharma

Several institutional investors have recently bought and sold shares of the business. Geode Capital Management LLC raised its position in ABVC BioPharma by 7.7% in the 4th quarter. Geode Capital Management LLC now owns 202,365 shares of the company’s stock valued at $431,000 after purchasing an additional 14,553 shares during the last quarter. Millennium Management LLC bought a new stake in shares of ABVC BioPharma during the third quarter worth $60,000. Finally, Citadel Advisors LLC bought a new stake in shares of ABVC BioPharma during the third quarter worth $48,000. Institutional investors own 11.38% of the company’s stock.

About ABVC BioPharma

ABVC BioPharma is a clinical-stage biotechnology company focused on the discovery and development of novel vaccine and immunotherapy candidates for oncology and infectious diseases. The company leverages a proprietary peptide-based platform to identify and synthesize immunogenic epitopes, aiming to stimulate targeted immune responses against tumor-associated and pathogen-derived antigens.

The company’s pipeline includes active immunotherapy programs designed to address a range of cancer indications, along with vaccine candidates targeting bacterial pathogens.